

# ● PRINTER RUSH ●

(PTO ASSISTANCE)

Application : <u>10/615563</u>	Examiner : <u>Berch</u>	GAU : <u>1624</u>
From : <u>LAS</u>	Location : <u>(IDC) FMF FDC</u>	Date : <u>9-8-05</u>
Tracking # : <u>6066000</u>		Week Date : <u>1-17-05</u>

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input checked="" type="checkbox"/> DRW	<u>7-7-2003</u>	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input type="checkbox"/> SPEC	_____	

**[RUSH] MESSAGE:** Attention Chief Draftsperson:  
There is a line through the drawings.

Thank you

**[XRUSH] RESPONSE:** \_\_\_\_\_

DRAWINGS CORRECTED

9-20-2005

**INITIALS:** [Signature]

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.  
 REV 10/04




FIGURE 1

## *In Vitro* inhibition of hlFBPase




FIGURE 2

# Displacement of AMP from hlFBPase




FIGURE 3

# Effect of Compound 2.7 on Gluconeogenesis from Dihydroxyacetone in Rat Hepatocytes




FIGURE 4A




FIGURE 4B

Inhibition of Glucose Production From Lactate  
Pyruvate (Rat Hepatocytes)




FIGURE 5

Compound 16.4 in 18h-Fasted, Normal Rats (i.p.)




FIGURE 6

Compound 2.7 in 18-hour fasted rats  
(20 mgs/kg, i.p.)




FIGURE 7




FIGURE 8



# 24h fasted ZDF Rats + COMPOUND 2.7




FIGURE 9A




FIGURE 9B

Gluconeogenesis from  $^{14}\text{C}$  bicarbonate in 24-h fasted ZDF Rats (20 week old)




FIGURE 10




FIGURE 11A




FIGURE 11B

Time, mins.